Trial Profile

A Phase IIa, Multicenter, Randomized, Controlled, Open Label Study to Evaluate the Efficacy of SENS-401 to Prevent the Ototoxicity Induced by Cisplatin in Adult Subjects With a Neoplastic Disease

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 07 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Arazasetron (Primary) ; Cisplatin
Indications Chemotherapy-induced damage; Hearing loss
Focus Proof of concept; Therapeutic Use
Acronyms NOTOXIS
Sponsors Sensorion

Most Recent Events

02 Apr 2025 Planned End Date changed from 31 May 2025 to 31 Aug 2025.
02 Apr 2025 Planned primary completion date changed from 31 Mar 2025 to 30 Jun 2025.
14 Mar 2025 According to Sensorion media release,topline data from this study to be reported by end of Q4 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com